• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    BridgeBio data show sustained benefit for achondroplasia drug

    BIOPHARMADIVE

    BridgeBio: Durable Infigratinib Results In Achondroplasia Study

    GLOBENEWSWIRE

    BridgeBio To Host Infigratinib Achondroplasia Phase 2 Data Call

    GLOBENEWSWIRE

    WITHDRAWN: FDA accelerated approval to infigratinib for metastatic cholangiocarcinoma

    FDA

    For $100M, BridgeBio partners with Kyowa Kirin on infigratinib

    FIERCE PHARMA

    BridgeBio Announces First Child Dosed in Phase 3 Clinical Trial for Infigratinib

    GLOBENEWSWIRE

    LianBio Announces Presentation of Data from Phase 2a Study of Infigratinib

    GLOBENEWSWIRE

    BridgeBio Pharma Announces Positive Feedback for Phase 3 of Infigratinib

    GLOBENEWSWIRE

    BridgeBio Presents Six Month Results from its Ph2 Cohort 5 Trial of Infigratinib

    GLOBENEWSWIRE

    BridgeBio to Present Six Month Results from Phase 2 Study of Infigratinib

    GLOBENEWSWIRE

    LianBio Announces Topline Results from Phase 2a Trial Evaluating Infigratinib

    GLOBENEWSWIRE

    Helsinn Group Announces European Medicines Agency’s (EMA) Acceptance for review

    GLOBENEWSWIRE

    BridgeBio and LianBio Announce Patient Treated in Phase 2a Trial of Infigratinib

    BUSINESSWIRE

    BridgeBio Pharma’s QED Therapeutics Presents Data on Infigratinib

    GLOBENEWSWIRE

    Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.